← Back to Search

Behavioral Intervention

Female Pathways Program for Substance Use Prevention in Native American Youth

N/A
Waitlist Available
Led By Lauren Tingey, PhD
Research Sponsored by Johns Hopkins Bloomberg School of Public Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Not cognitively or visually impaired (able to complete assessments)
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 6- and 12-months post implementation
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a program called 'Asdzaan Be'eena: Female Pathways' (AB) for AI girls aged 10-14 and their caregivers. The program aims to prevent early substance use and teen pregnancy by enhancing self-esteem and cultural identity through regular sessions. It addresses specific health issues faced by AI communities.

Who is the study for?
This trial is for Navajo female adolescents and their caregivers living within 50 miles of Chinle or Tuba City, Arizona. Participants must speak English, be willing to complete assessments and be randomized. Caregivers should have a girl aged 10-14 years old to enroll with them in the study.
What is being tested?
The 'Asdzaan Be'eena' program (Female Pathways) is being tested for its effectiveness in reducing early substance use and sexual activity among Native American youth. This research involves a randomized controlled trial to see if it can lower teen pregnancy and substance abuse risks.
What are the potential side effects?
Since this intervention is an educational program rather than a medical treatment, there are no direct physical side effects expected from participating in the Asdzaan Be'eena program.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can see well and think clearly enough to complete tests.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 6- and 12-months post implementation
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 6- and 12-months post implementation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in mean score on externalizing and internalizing behaviors
Change in parent reported monitoring
Change in parent reported parent-youth communication scale
+6 more
Secondary study objectives
Change in caregiver cultural connectedness
Change in caregiver parenting agency
Change in caregiver parenting self-efficacy
+10 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
The program consists of 11 weekly sessions conducted with girls ages 10-14 and their female caregivers. 5 of the 11 sessions will be taught to groups of 9-13 girls and their female caregivers, and 6 of the sessions will be taught to individual girl/female caregiver dyads. The choice to use a mix of group- and individual sessions is based on findings from the formative phase indicating certain topics should be taught in groups (e.g. Navajo history and reproductive health 101), and certain topics be taught in individual dyads (e.g. family values and the clan system).
Group II: ControlActive Control1 Intervention
Girls and their female caregivers randomized to the control group will receive 4 retention incentives that are mailed to them monthly. These incentives will each be \<$10 per dyad, examples include: water bottles, lanyards, pencil cases and tote bags. The control condition was selected by community members and allows for minimal contamination and/or overlap between the AB curriculum and control group

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The Asdzaan Be'eena' program uses culturally tailored education and support to modify risk and protective factors related to early substance use and sexual debut. Common treatments for sexual activity that align with this approach include sex education, attitude restructuring, and behavioral interventions. These treatments work by providing knowledge, reshaping attitudes towards sexual health, and promoting healthy behaviors. This matters for patients because it empowers them with the information and skills needed to make informed decisions, reduce risky behaviors, and enhance protective factors, ultimately leading to improved sexual health outcomes.
Treatment for premature ejaculation through male-only groups.Group vs. couple treatment of sexual dysfunctions.The stepwise development of an interactive web-based sex education programme for subfertile couples: the Pleasure &amp; Pregnancy programme.

Find a Location

Who is running the clinical trial?

Children's Bureau - Administration for Children and FamiliesOTHER
22 Previous Clinical Trials
38,635 Total Patients Enrolled
Johns Hopkins Bloomberg School of Public HealthLead Sponsor
431 Previous Clinical Trials
2,134,376 Total Patients Enrolled
1 Trials studying Sexual Activity
65 Patients Enrolled for Sexual Activity
Lauren Tingey, PhDPrincipal InvestigatorJohns Hopkins Bloomberg School of Public Health
2 Previous Clinical Trials
1,291 Total Patients Enrolled
Jennifer Richards, PhDPrincipal InvestigatorJohns Hopkins Bloomberg School of Public Health
1 Previous Clinical Trials
160 Total Patients Enrolled

Media Library

Asdzaan Be'eena Program (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04863729 — N/A
Sexual Activity Research Study Groups: Control, Intervention
Sexual Activity Clinical Trial 2023: Asdzaan Be'eena Program Highlights & Side Effects. Trial Name: NCT04863729 — N/A
Asdzaan Be'eena Program (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04863729 — N/A
~129 spots leftby Sep 2025